Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06570798 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
A Phase 2 study of Systemic Lupus Erythematosus and Active Refractory Rheumatoid Arthritis, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06570798: Recruiting Phase 2 study of Systemic Lupus Erythematosus and Active Refractory Rheumatoid Arthritis, sponsored by Amgen.
NCT06570798 is a Phase 2 study of Systemic Lupus Erythematosus and Active Refractory Rheumatoid Arthritis that is actively recruiting participants, run by Amgen. The registered enrollment target is 220 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06570798, a Phase 2 study of Systemic Lupus Erythematosus and Active Refractory Rheumatoid Arthritis, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).
Conditions Studied
Interventions
- DRUG Inebilizumab
- DRUG Blinatumomab
Study Locations (20)
Florida
- Vida Research Center - Hialeah
- Homestead Associates In Research Inc - Homestead
- Vitaly Clinical Research - Miami
- Bioresearch Partner Coral Terrace - South Miami
New York
- Northwell Health - Great Neck
- Westchester Medical Center - Hawthorne
- Columbia University Medical Center - New York
- University of Rochester Medical Center - Rochester
Ohio
- MetroHealth Medical Center - Cleveland
- Cleveland Clinic Foundation - Cleveland
Other
- Cliniques Universtaire Saint Luc Universite Catholique de Louvain - Brussels
- Universitair Ziekenhuis Gent - Ghent
Arizona
- HonorHealth Research and Innovation Institute - Scottsdale
Colorado
- University of Colorado - Aurora
Louisiana
- University Medical Center New Orleans - New Orleans
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2029-03-09 |
| Phase | Phase 2 |
What NCT06570798 shows while recruiting
NCT06570798 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (42% lower).
The record links to 2 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Inebilizumab is the first listed.
NCT06570798 names 20 study sites across 12 states, led by Florida, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT06570798 about?
NCT06570798 is a clinical study titled "A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases". The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active...
What is the current status of trial NCT06570798?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2025-07-16. Estimated completion is 2029-03-09.
What conditions does trial NCT06570798 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis.
What interventions are being tested in trial NCT06570798?
The interventions under investigation include: Inebilizumab (DRUG), Blinatumomab (DRUG).
Who is sponsoring clinical trial NCT06570798?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06570798 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06570798's enrollment target sits among peer trials
220 39th of 99 higher than 61 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI